Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Discovery Genomics Inc.

This article was originally published in Start Up

Executive Summary

Discovery Genomics Inc.'s Sleeping Beauty transposon vector is non-viral, but it can integrate into the genome to achieve long-term expression. DGI uses it in two parts: the transposon vector carries the therapeutic genes, and the transposase enzyme moves it from the vector into the chromosome. When delivered to cells at the same time, the transposase cuts the therapeutic gene out of the vector and inserts it into the host chromosome, much like you cut and paste using a word processor.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel